FDA approves GSK’s Nelkarmi for pretreated ALK-positive lung cancer
GSK’s Nelkarmi earned accelerated FDA approval for previously treated ALK-positive NSCLC, with ALKOVE-1 response rates of 49% and 32% after prior therapy.

Stories
U/AUTHOR
6 filings logged
GSK’s Nelkarmi earned accelerated FDA approval for previously treated ALK-positive NSCLC, with ALKOVE-1 response rates of 49% and 32% after prior therapy.
